Literature DB >> 10663038

[Calciphylaxis: ischemic tissue necrosis in chronic renal failure. Case report and review of the literature].

G Schwarz1, F Laukhuf, F Bittinger, J Knop, J Saloga.   

Abstract

Calciphylaxis is a rare but potentially life-threatening complication in chronic renal failure. It is characterized by ischemic tissue necrosis primarily of the skin. The typical histopathologic finding is microvascular calcification with endovascular fibrosis. Patients typically present with violaceous, mottled and painful lesions which tend to progress to non-healing ulcers and necrosis. Most frequently the lower extremities are involved in a symmetric fashion but the trunk may also be affected. Sepsis from superinfection of the lesions accounts for the high mortality of this disease which is of importance for dermatologists and nephrologists alike. 61-year-old female patient developed lesions of calciphylaxis on both calves two years after beginning hemodialysis to treat renal failure due to diabetic glomerulosclerosis. We discuss aspects of the pathogenesis of calciphylaxis, as well as diagnosis, treatment and means of prevention, and review the current literature.

Entities:  

Mesh:

Year:  2000        PMID: 10663038     DOI: 10.1007/s001050050008

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  5 in total

1.  [Painful ulcerating livid erythema in a 58-year old patient].

Authors:  D Hoeft; U Hillen; M Goos; J Dissemond
Journal:  Hautarzt       Date:  2004-06       Impact factor: 0.751

2.  [Disseminated skin ulcerations associated with chronic renal failure].

Authors:  S Weckesser; H Goebel; J Donauer; C M Schempp
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 3.  [Vascular emergencies in dermatology].

Authors:  B Kahle
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

Review 4.  [Dialysis associated skin changes].

Authors:  H Ulrich; M Landthaler; U Hohenleutner
Journal:  Hautarzt       Date:  2004-05       Impact factor: 0.751

5.  Tumoral calcinosis revisited: pathophysiology and treatment.

Authors:  Gregor Möckel; Frank Buttgereit; Karsten Labs; Carsten Perka
Journal:  Rheumatol Int       Date:  2003-09-12       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.